U.S. markets close in 5 hours 16 minutes
  • S&P 500

    4,630.29
    +63.29 (+1.39%)
     
  • Dow 30

    34,850.11
    +366.39 (+1.06%)
     
  • Nasdaq

    15,728.68
    +190.99 (+1.23%)
     
  • Russell 2000

    2,247.71
    +48.80 (+2.22%)
     
  • Crude Oil

    68.01
    +1.83 (+2.77%)
     
  • Gold

    1,790.10
    +13.60 (+0.77%)
     
  • Silver

    22.68
    -0.14 (-0.59%)
     
  • EUR/USD

    1.1351
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.4820
    +0.0390 (+2.70%)
     
  • GBP/USD

    1.3319
    +0.0018 (+0.13%)
     
  • USD/JPY

    112.9070
    -0.2730 (-0.24%)
     
  • BTC-USD

    58,492.35
    -296.93 (-0.51%)
     
  • CMC Crypto 200

    1,492.07
    +22.99 (+1.56%)
     
  • FTSE 100

    7,138.23
    +78.78 (+1.12%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Syndax Posts Better-Than-Feared Quarterly Loss, Sales Beat Estimates

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped 1.2% to close at $23.30 on March 8.

Syndax (SNDX) incurred a loss of $0.44 per share in 4Q, compared to the $0.49 loss per share estimated by analysts. Total revenue came in at $380,000, topping analysts’ expectations of $200,000.

The company’s research and development expenses were $15.5 million in the quarter, up 63.2% year-over-year. Total operating expenses stood at $20.2 million, up 38.4%. (See Syndax stock analysis on TipRanks)

Syndax CEO Briggs W. Morrison said, “We expect 2021 will be a year of immense progress across our two highly promising programs aimed at addressing key areas of unmet need, coupled with a sharp focus on pipeline expansion.”

“Notably, we plan to present data from the Phase 1 portion of our ongoing AUGMENT-101 trial of SNDX-5613, our selective menin inhibitor, in patients with acute leukemias,” Morrison added.

For 2021, the company projects research and development expenses to be in the range of $90 million to $100 million. Total operating expenses are anticipated to range from $110 million to $120 million.

For 1Q, research and development expenses are forecasted to be in the range of $25 million to $30 million, with total operating expenses in the range of $30 to $35 million.

Following the 4Q results, Stifel Nicolaus analyst Konstantinos Aprilakis maintained a Buy rating and a price target of $39 (67.4% upside potential) on the stock as the analyst is “enthusiastic about the menin space.”

Aprilakis expects “the company to continue finding success with SNDX-5613, its lead asset and menin/MLL inhibitor for potential use in acute leukemias, and axatilimab, an anti-CSF-1R antibody currently being developed in cGVHD.”

Syndax shares have exploded almost 108% over the past year, while the stock still scores a Strong Buy consensus rating based on 3 unanimous Buys. That’s alongside an average analyst price target of $35.33, which implies 51.6% upside potential to current levels.

Additionally, Syndax scores an 8 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.

Related News:
Hibbett 4Q Profit Exceeds Estimates As E-commerce Sales Boom; Shares Tank 4%
Big Lots’ 4Q Profit Beats Analysts’ Estimates As Comparable Sales Rise; Shares Gain 2%
Cooper’s 1Q Results Beat The Street Consensus; Street Says Buy

More recent articles from Smarter Analyst: